Avricore Health Inc.
AVCR.V
Toronto Stock Exchange Ventures0.06
CAD
+0.01
- -
Avricore Health Inc.
AVCR.V
(Toronto Stock Exchange Ventures)
Recent
price
0.06
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Avricore Health Inc. is a pharmacy services innovator specializing in pharmacy-based digital health solutions. The company provides a turnkey, cloud-connected point-of-care testing platform, HealthTab™, designed to support pharmacists in delivering clinical services and managing chronic diseases. Its main products include a comprehensive test menu offering up to 23 key biomarkers such as HbA1c, lipid profiles, and eGFR for screening and managing conditions like diabetes and heart disease. HealthTab™ also integrates rapid diagnostic tests for bacterial and viral infections, including strep and COVID-19. The platform combines best-in-class point-of-care devices with a secure cloud infrastructure that enables real-time data reporting, patient access, and seamless integration with third-party applications via APIs. Founded in 2013 and headquartered in Vancouver, British Columbia, Avricore primarily operates in the United Kingdom and Canada with an expanding focus on the UK healthcare market. The company’s services empower pharmacists as frontline care providers while giving patients greater control over their health through convenient, in-pharmacy testing and health data management. The HealthTab™ network model supports multiple revenue streams, including equipment leasing, consumables, disease prevention programs, decentralized clinical trials, and real-world data collection to inform health organizations and clinical research. In recent developments, Avricore has strategically shifted its focus to accelerate growth in the UK market, concluding its previous Canadian partnership with Shoppers Drug Mart and redeploying resources accordingly. In 2024 and 2025, the company expanded HealthTab™ into new NHS Integrated Care Board regions, including North Central London and North East London, as part of a groundbreaking pharmacy-led cardiovascular project and other NHS initiatives. It secured reseller agreements, such as with Abbott Rapid Diagnostics UK & Ireland, to distribute rapid testing devices. The company also integrated its platform with the UK's leading patient personal health record system, Patients Know Best, enhancing data accessibility and patient engagement. Leadership updates include the appointment of Rodger Seccombe as CEO in mid-2025. Avricore reported net profitability in early 2024 and strong revenue growth with a record year in 2024, demonstrating its progress in scaling operations and expanding clinical service offerings within community pharmacies. Overall, Avricore Health Inc. operates in the healthcare technology and pharmacy services segment, targeting pharmacies, healthcare providers, and patients with scalable digital solutions for chronic disease management and point-of-care diagnostics primarily in the UK and Canadian markets. The company emphasizes innovation in pharmacy practice and accessible health information to improve outcomes. This description is based on the latest company updates, financial reports, strategic partnerships, and product offerings through 2025.
HealthTab™ to Power NHS Pilot